Deutsch English
← back to archive
AI & Technology · 526 words · MN-260605-0103

Biotech firms want AI to reverse ageing – and a $610 billion market is

waiting

MuckyNews reading

Ageing is like software building up bugs – at least, that's how the CEO of METiS TechBio puts it. The idea is that AI can read, rewrite, and possibly even reverse these errors in our genetic code. The practical starting point: repairing ageing immune cells like T-cells, making older people less vulnerable to disease. It sounds like science fiction, but the money is very real. The global longevity market is valued at $610 billion. METiS, a six-year-old startup from Beijing, just pulled in nearly $270 million from its Hong Kong IPO in late May, with BlackRock and UBS jumping in as cornerstone investors. Right now, the US clearly dominates the field of cellular reprogramming—home to 57 percent of all longevity companies and 84 percent of deal volume, fueled by massive private investment. What's visible here is a huge, still-experimental market where AI acts as an accelerant. The science is in its infancy, but the capital isn't waiting for proof. The real pressure point isn't whether the technology will eventually deliver; it's that astronomical sums are already flowing into a promise with an entirely open outcome.

Short version

  • **What happened?** Biotech startups like METiS TechBio are using AI to

target ageing at the cellular level and are raising massive capital.

  • **Who is involved?** METiS TechBio (Beijing), investors like BlackRock

and UBS, and the US biotech scene as the dominant global player.

  • **Why does it matter?** A potential $610 billion market is at stake. AI

is radically accelerating development before the science is fully baked.

  • **What is still open?** Whether cellular reprogramming actually works in

humans to slow or reverse ageing.

  • **What is the real pressure point?** Giant financial flows are pouring

into a high-risk, experimental technology simply because the market potential is so enticing.

Perspective delta

hongkong_china_asia The SCMP material frames the topic primarily as a business opportunity and a technological race. The CEO's metaphor—ageing as a software bug—is adopted without critique as a handy explanation. The piece highlights the funding successes of Chinese firms like METiS and the sheer size of the market. What gets downplayed is the fact that the entire field is still in its early stages. The massive dominance of the US is backed by data, but it's used more as a benchmark for the competition rather than an indicator of structural advantages. Western institutional money from players like BlackRock is framed as a vote of confidence, not as speculation.

Source base / limits

The source base is extremely narrow. The entire report relies on a single article from the South China Morning Post. There is no counter-perspective, no critical scientific assessment, and no voice questioning the technology's risks or the plausibility of its promises. The picture is therefore entirely one-sided, driven by market and investor optimism.

Sources / basis

  • MuckyNews container ID: MN-20260605-103
  • Source outlets/stations: South China Morning Post (SCM)
  • Perspective groups: hongkong_china_asia
  • Article count: 1
  • Source count: 1
  • Perspective count: 1
  • Approximate raw text size: 2169 characters